A Norwegian study found a slight increase in type 1 diabetes diagnoses in children following rotavirus vaccine introduction, but researchers caution against linking the two, highlighting broader environmental factors influencing disease trends.
Norway’s rapid rollout of the rotavirus vaccine has been linked to a modest rise in childhood type 1 diabetes, but researchers say the shot is probably not to blame.
A nationwide study from the University of Oslo, presented at the European Association for the Study of Diabetes meeting in Milan and published in Diabetologia, tracked every child born in Norway between 2007 and 2019. The researchers followed 740,744 children from six months to age five and found that type 1 diabetes diagnoses in the under-fives rose by 11% after the country added the monovalent Rotarix vaccine to its childhood immunisation schedule in September 2014. Among the full cohort, 846 children were diagnosed before their fifth birthday.
The result might sound alarming, but the team built its analysis to test whether the timing reflected a true vaccine effect or something else. According to the study, uptake of the rotavirus vaccine climbed quickly after introduction, creating a clear divide between children born before and after the policy change. The authors then used an interrupted time series design, comparing the post-rollout pattern with the trend that would have been expected had nothing changed. They also ensured the follow-up period was the same for children born on either side of the introduction date, reducing a common source of bias.
Even so, the most telling part of the paper was not the rotavirus finding itself, but what happened when the researchers looked at other changes in Norway’s immunisation programme. The same kind of rise appeared after the introduction of the hepatitis B vaccine in 2016 and after the switch from the 7-valent to the 13-valent pneumococcal vaccine in 2011. Because neither of those changes has a plausible link to type 1 diabetes, the repeated pattern suggests that the increase was more likely driven by some other environmental shift affecting Norwegian children than by rotavirus vaccination.
The authors also examined whether other recent changes could explain the trend, including the coronavirus pandemic and updated prenatal care advice on iron testing. They concluded those explanations were unlikely to account for the pattern they observed. A separate adjusted analysis found that children who received two doses of the rotavirus vaccine had a hazard ratio of 1.17 for type 1 diabetes compared with unvaccinated children, but that estimate was not statistically significant.
Researchers involved in the work say the broader message is one of caution in interpreting vaccine safety signals from population trends. Type 1 diabetes has been rising over time in many countries, and when that upward drift overlaps with a policy change, the two can look linked even when they are not. The Norwegian study does not support the idea that rotavirus vaccination raises the risk of type 1 diabetes in early childhood, the authors say, but it does underline the need to keep searching for the environmental factors that may be pushing rates higher.
That conclusion matters beyond Norway. The country uses Rotarix alone, while other European nations use different rotavirus vaccine formulations, giving researchers a chance to compare outcomes across settings. For parents, the practical takeaway is reassuring: rotavirus vaccination remains an important tool for preventing severe stomach infections in young children, and this study’s own control analyses point away from the vaccine as the cause of the diabetes increase.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
